Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review

Tulin Ergun, Dilek Seckin-Gencosmanoglu, Andac Salman, Zuleyha Ozgen, Esra Sarac Ocak, Erol Avsar, Nese Imeryuz

ABSTRACT

Patients with psoriasis are at an increased risk of developing liver disease due to various factors. The existing data regarding the treatment of psoriasis patients with associated liver cirrhosis is limited. We report four patients of psoriasis with liver cirrhosis who were treated with TNF-alpha inhibitors for a mean duration of 35.4 months. Two patients were treated with etanercept, one with adalimumab and one was treated with both infliximab and etanercept. Three patients tolerated the treatment well without any deterioration of liver disease whereas one died of progressive liver disease. Although large-scale, controlled studies are needed, this case series provides insights regarding the long-term safety of TNF-alpha inhibitors in patients with psoriasis and liver cirrhosis.

Key words: Adalimumab, cirrhosis, etanercept, infliximab, psoriasis, TNF-alpha inhibitors

INTRODUCTION

Psoriasis patients are at a higher risk of developing liver disease due to various reasons. They are at an increased risk of non-alcoholic fatty liver disease, one of the main causes of liver cirrhosis.[1,2] Another factor is the over-consumption of alcohol which is common among psoriasis. It is the most common cause of liver cirrhosis in the Western world.[3] Finally, most systemic agents used for the treatment of psoriasis are hepatotoxic, especially methotrexate.[4] Although relatively safer in terms of liver injury, TNF-alpha inhibitors have also been reported to be hepatotoxic.[4,5] Therefore, current guidelines suggest regular monitoring of all psoriasis patients using systemic therapy for signs of liver toxicity.[6,7]

Although there are guidelines and consensus reports for the treatment of psoriasis patients with coexisting hepatitis B virus or hepatitis C virus infection, the data on treatment of patients with liver cirrhosis is limited. A few cases have been described where TNF-alpha inhibitors were safely used in the treatment of psoriasis with coexistent liver cirrhosis.[8-10] The safety of using TNF-alpha inhibitors in patients with liver cirrhosis has been supported in case reports of inflammatory bowel disease.[11-13] All this information is rather inadequate. Therefore, we would like to report four psoriasis patients with liver cirrhosis who were treated with TNF-alpha inhibitors for a relatively long period. A review of the relevant literature follows.

CASE REPORTS

Case 1

A 63-year-old man with severe generalized plaque psoriasis was treated with topical corticosteroids and emollients for six years. His medical history was not significant except for chronic obstructive pulmonary...
Ergun, et al. Use of TNF-alpha inhibitors in psoriasis with cirrhosis
disease. Laboratory tests including complete blood
count, prothrombin time, liver transaminases, serum bilirubin, electrolytes, lipids and creatinine
were within the normal range. He had upper
gastrointestinal bleeding, and abdominal ultrasound
revealed liver changes consistent with cirrhosis.
Gastroscopy revealed portal gastropathy and grade
I and II esophageal varices. Markers of autoimmune
hepatitis, hepatitis A, B and C were negative. As
investigations did not identify the cause of cirrhosis,
he was labelled to have cryptogenic cirrhosis. He was
treated with etanercept, 50 mg twice weekly following
which his skin condition significantly improved. A
PASI 75 response was achieved by the end of the third
month of therapy. During the two years of follow-up, his
serum albumin levels had only marginally increased.
Serum transaminases were assessed monthly and
remained within the normal range. The patient was in
remission during this entire period [Table 1].

Case 2
A 62-year-old man had a ten-year history of psoriasis
and past infection with hepatitis C virus. He also
had diabetes mellitus, coronary artery disease and
liver cirrhosis. The cirrhosis was probably related to
non-alcoholic fatty liver disease secondary to hepatitis
C virus infection. His previous treatments included
methotrexate, acitretin, cyclosporine and
phototherapy. She had a liver biopsy which was
consistent with chronic hepatitis C virus infection
and grade III fibrosis. As the hepatitis C virus RNA
levels were undetectable, she was not given interferon
therapy. She was treated with infliximab in a dose of 5
mg/kg body weight. A PASI 50 response was achieved
after the third infusion but secondary unresponsiveness
developed at the end of five months. We then decided
to switch to etanercept. Repeat screening tests revealed
Table 1: Demographic features, treatment and outcome of the cases

| Characteristics               | Case 1       | Case 2       | Case 3       | Case 4       |
|-------------------------------|--------------|--------------|--------------|--------------|
| Age, gender                   | 63, male     | 62, male     | 60, female   | 58, male     |
| Diagnosis, duration of disease (years) | Ps, 6       | Ps, 10      | Ps, PsA, 20  | Ps, PsA, 16  |
| Concurrent disease            | COPD         | NAFLD, DM, CAD | NAFLD, HCV  | NAFLD, HCV  |
| Cause of cirrhosis            | Cryptogenic  | NAFLD, DM, CAD | NAFLD, HCV  | Alcoholism   |
| Baseline PASI score           | 25.1         | 32.4         | 31.5         | 17.8         |
| Treatment duration (months)   | ETA, 2×50 mg/week, 24 | ETA, 2×50/1×50 mg/week, 27 | IFX 5 mg/kg, 5 | ADA, 70     |
| Treatment outcome             | PASI 75      | PASI 75      | PASI 50      | PASI 90      |
| Baseline AST/ALT (U/L)*       | 32/33        | 61/43        | 42/39        | 38/29        |
| Last visit AST/ALT (U/L)*     | 23/15        | 41/26        | 56/36        | 31/30        |
| Baseline albumin (g/dL)*      | 3.6          | 3.5          | 4.1          | 4.5          |
| Last visit albumin (g/dL)*    | 4.7          | 3.5          | 3.5          | 4.2          |
| Baseline PT/INR*              | 14.1/1.17    | 13.6/1.1     | 15.5/1.33    | 14.2/1.19    |
| Last visit PT/INR*            | 12.6/1       | 14/1.15      | 16.4/1.42    | 13.8/1.1     |
| Remission of psoriasis        | Yes          | Yes          | Active disease | Yes         |
| Current status                | Alive        | Alive        | Dead         | Alive        |

Abnormal laboratory values are marked in bold. *Normal ranges: AST: 10-37 U/L, ALT: 10-40 U/L, Albumin: 3.5-5.4 g/dL, PT: 11-13 s. Ps: Psoriasis, PsA: Psoriatic arthritis, COPD: Chronic obstructive pulmonary disease, NAFLD: Non-alcoholic fatty liver disease, HCV: Hepatitis C virus, DM: Diabetes mellitus, DL: Dyslipidemia, PASI: Psoriasis area severity index, ETA: Etanercept, IFX: Infliximab, ADA: Adalimumab, CAD: Coronary artery disease, PSL: Psoriasis area severity index, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, PT: Prothrombin time, INR: International normalized ratio
positive hepatitis C antibodies and positive hepatitis C virus RNA. She had mild thrombocytopenia, hypoalbuminemia, hyperbilirubinemia and a Child-Pugh’s score of 5. No interferon therapy was given to prevent probable liver failure. Etanercept was initiated in a dose of 50 mg, twice weekly for severe psoriasis and psoriatic arthritis, without any additional antiviral therapy. Besides the significant improvement of her psoriasis and arthritis, hepatitis C virus RNA became negative within six months. Etanercept was later discontinued due to non-compliance. Following this, her liver functions progressively worsened and she developed ascites and jaundice. She died a year later with hepatitis C virus infection and non-alcoholic fatty liver disease - induced liver failure as the cause of death. Her hepatitis C virus RNA was negative at the time of death.

Case 4
A 58-year-old man with chronic alcoholism had psoriasis and psoriatic arthritis for 16 years. He also had diabetes mellitus, osteoporosis and dementia. His previous treatments included topical corticosteroids, vitamin D analogues, narrow band ultraviolet B, psoralen and ultraviolet A and methotrexate. He was diagnosed to have liver cirrhosis due to alcoholism. He was treated with adalimumab following which a PASI 90 response was achieved in two months. He is still in remission after 70 months of therapy and does not have any deterioration in liver function. His prothrombin time was shorter compared to the pre-treatment value. This may be attributable to abstinence from alcohol or relief of inflammation with treatment.

DISCUSSION
The literature on treatment of psoriasis with TNF-alpha inhibitors in the setting of cirrhosis is limited. Using a PubMed search with the keywords “liver cirrhosis, psoriasis and psoriasis treatment,” we found three publications. These were from the same center in Germany and each publication reported one patient. These patients had common features such as psoriatic arthritis, diabetes and hereditary alpha-1 antitrypsin deficiency that led to histologically proven micronodular liver cirrhosis. The successful use of infliximab in a 52-year-old man with normal liver enzymes was reported by them. Another case report was of a 53-year-old man with a stable course of liver enzymes during the twelve weeks of treatment with etanercept. That patient was previously treated with infliximab but it had to be stopped due to monetary constraints. The last publication described the safe use of adalimumab in a psoriasis patient who had stable liver enzymes during the eight months of therapy.

Liver cirrhosis is an advanced stage of liver fibrosis due to chronic liver injury. The most common causes are alcoholism, viral hepatitis, autoimmune hepatitis and non-alcoholic fatty liver disease. Psoriasis patients have multiple risk factors for cirrhosis such as alcoholism, non-alcoholic fatty liver disease and drug-induced toxic hepatitis. Three of our patients had similar findings while one case was diagnosed to have cryptogenic liver cirrhosis.

We report four cases with severe psoriasis and liver cirrhosis successfully treated with TNF-alpha inhibitors. The mean duration of treatment was 35.4 months. No clinical or laboratory signs of deteriorating liver function was seen in three cases during the course of treatment. However, progressive liver disease led to death in one case. In that particular case, TNF-alpha inhibitors were initiated when the patient had mild cirrhosis (Child-Pugh score 5) and non-replicative hepatitis C virus infection. The prior use of other hepatotoxic agents (methotrexate and acitretin), poorly controlled diabetes, non-alcoholic steatohepatitis and hepatitis C virus infection may have precipitated fatal liver failure. Their impact on the outcome could not be determined separately.

Most systemic anti-psoriatic agents are hepatotoxic to some extent. Methotrexate is the most significant and causes fibrosis in 4% of cases. Cyclosporine causes cholestasis due to intrahepatic vasoconstriction. Acitretin causes transient and reversible elevation of liver enzymes in up to 15% of patients and there are a few reports of severe hepatotoxic reaction progressing to liver cirrhosis. All three TNF-alpha inhibitors approved for the treatment of psoriasis can cause hepatotoxicity. With infliximab, liver toxicity is rare and reported in about one case per 16,500 treated people per year. Hepatotoxicity can manifest as drug-induced hepatitis, autoimmune hepatitis, cholestatic liver injury, reactivation of hepatitis B virus or hepatitis C virus and fulminant hepatic failure.

Two of our cases had hepatitis C virus infection. However, it is not a contraindication to TNF-alpha inhibitor therapy as these agents do not increase transaminase levels or viral load in the short-term.
Long-term data is lacking. Recently, an improvement in liver function and viral load during TNF-alpha inhibitor therapy has been reported in two out of 15 patients who had replicative hepatitis C virus infection and psoriatic arthritis. The inhibition of hepatitis C virus-related apoptotic cell death and the suppression of viral replication mediated by inflammatory cytokines including TNF-alpha may explain the positive effect of these drugs on liver function tests.

According to a recent guideline on systemic anti-psoriatic therapy, conventional drugs including methotrexate, acitretin and cyclosporine are contraindicated in patients with severe liver disease whereas TNF-alpha inhibitors and ustekinumab are not. Apart from psoriasis, TNF-alpha inhibitors have been used in patients with inflammatory bowel disease and cirrhosis and also in primary biliary cirrhosis. The literature regarding the safety of TNF-alpha inhibitors in the presence of cirrhosis with either psoriasis or inflammatory bowel disease is sparse and limited to case reports. Similarly, the data on the safety of ustekinumab in the setting of cirrhosis is lacking and it may cause reactivation of hepatitis B virus and hepatitis C virus infection.

**CONCLUSION**

Any patient with liver disease should be referred to a gastroenterologist before initiating TNF-alpha inhibitor therapy. As the available information provides limited data on safety, the possible risks and benefits of using these drugs in patients with cirrhosis should be evaluated on an individualized basis before initiating treatment. Special attention must be paid to infectious adverse effects as these patients are at a higher risk. They should be regularly followed up and closely monitored with good collaboration between the dermatologist and gastroenterologist.

The present case series provides data on the long-term use of TNF-alpha inhibitors in patients cirrhosis with. Although large-scale, controlled studies are necessary to assess the long-term safety and efficacy, it is difficult to design such studies due to ethical concerns. Post-marketing surveillance data may provide more information on this topic.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Krueger G, Ellis CN. Psoriasis – Recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53 1 Suppl:1:S94-100.
2. Gisondi P, Tarqher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-64.
3. Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol 2011;50:1323-31.
4. Menter A, Korman NJ, Elms CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines on the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
5. Ghabril M, Bonkovsky HL, Kum C, Davenet T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-\( \alpha \) antagonists: Analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013;11:558-564.
6. Zweegers J, de Jong EM, Nijsten TE, de Bes J, te Booj M, Borgonjen RJ, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venerology. Dermatol Online J 2014;20. pii: Doj_21769.
7. Hsu S, Papp KA, Lebwohl MG, Baigel J, Blauvelt A, Duffin KC, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012;148:95-102.
8. Lehnen M, Franckson T, Knab J, Hoefl D, Grabbe S, Dissemond J. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis. Br J Dermatol 2005;153:212-4.
9. Lehnen M, Franckson T, Korber A, Grabbe S, Dissemond J. Etanercept therapy of psoriatic arthritis in a patient with liver cirrhosis. Acta Derm Venereol 2005;85:351-2.
10. Piol S, Dissemond J. Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver. J Am Acad Dermatol 2008;59 5 Suppl: S117-8.
11. Dhere T. Use of biologics in inflammatory bowel disease patients with cirrhosis. Inflamm Bowel Dis 2011;17:E15-6.
12. Abdelmalek MF, Liu C, Valentine JR. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Czohn’s disease. Am J Gastroenterol 2007;102:1333-4.
13. Carrión S, Marín I, Domènech E. Infliximab use in a patient with ulcerative colitis and alcoholic cirrhosis with portal hypertension. J Crohns Colitis 2008;2:271-2.
14. Chalongitas E, Papatheodoridis GV, Vangelis M, Terreni N, Patch D, Burroughs AK. Systematic review: The model for end-stage liver disease – Should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22:1079-89.
15. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non-alcoholic steatohepatitis (NASH). Z Gastroenterol 2008;46:1369-71.
16. Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013;48:839-46.
17. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
18. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004;99:1160-74.
19. Sass DA, Chang P, Chopra KB. Non-alcoholic fatty liver disease: A clinical review. Dig Dis Sci 2005;50:171-80.
20. Dogra S, Mahajan R. Systemic methotrexate therapy for
psoriasis: Past, present and future. Clin Exp Dermatol 2013;38:573-88.
21. Erdem SR, Emre-Aydinöz S, Atilla P, Cakar AN, Dalkara T, Bolay H, et al. Cyclosporine A-induced acute hepatotoxicity in guinea pigs is associated with endothelin-mediated decrease in local hepatic blood flow. Life Sci 2011;88:753-60.
22. Ormerod AD, Campalani E, Goodfield MJ. BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010;162:952-63.
23. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: Discussion of a case and review of the literature. Intern Emerg Med 2010;5:193-200.
24. Pompili M, Biolato M, Miele L, Greico A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19:7867-73.
25. Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015;13:602-8.
26. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: Two cases. Clin Rheumatol 2007;26:261-4.
27. Zylberberg H, Rimanicol AC, Pol S, Masson A, De Groote D, Berthelot P, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity. J Hepatol 1999;30:185-91.
28. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
29. Kubo S, Iwata S, Saito K, Tanaka Y. Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine 2011;78:335-6.
30. Ogata A, Terabe F, Nakanishi K, Kawai M, Kuwahara Y, Hirano T, et al. Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint Bone Spine 2009;76:105-7.
31. Spadaro A, Scrivo R, Ricciieri V, Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2008;75:87-9.
32. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013;169:1295-303002E.